Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases

Patent metadata

Field	Value
Publication number	US-9422264-B2
Application number	US-201414252425-A
Country	US
Kind code	B2
Filing date	Apr 14, 2014
Priority date	Dec 7, 2007
Publication date	Aug 23, 2016
Grant date	Aug 23, 2016

Abstract

The present invention relates to novel carbamate-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.

First claim

The invention claimed is:

1. A method for treating anxiety disorders, stress-dependent anxiety disorders, or depressive disorders, the method comprising administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof to a subject in need thereof,

in which
R 1 is hydrogen, methoxy or ethoxy;
R 2 is hydrogen or methoxy;
R 3 is hydrogen, methyl, ethyl, n-propyl or isopropyl;
X 1 and X 2 are N or CH, with the proviso that X 1 and X 2 are not simultaneously N.

2. The method of claim 1 , in which R 1 is hydrogen or methoxy.

3. The method of claim 1 , in which R 3 is hydrogen, methyl or ethyl.

4. The method of claim 1 , in which X 1 is N and X 2 is CH.

5. The method of claim 1 , in which X 1 is CH and X 2 is N.

6. The method of claim 1 , in which X 1 is CH and X 2 is CH.

7. The method of claim 1 , in which
R 1 is methoxy;
R 2 is methoxy;
R 3 is methyl or ethyl;
X 1 is CH; and
X 2 is N.

8. The method of claim 1 , in which
R 1 is methoxy;
R 2 is H;
R 3 is methyl or ethyl;
X 1 is CH; and
X 2 is N.

9. The method of claim 1 , in which
R 1 is H;
R 2 is methoxy;
R 3 is methyl or ethyl;
X 1 is CH; and
X 2 is N.

10. The method of claim 1 , in which
R 1 is H;
R 2 is H;
R 3 is methyl or ethyl;
X 1 is CH; and
X 2 is N.

11. The method of claim 1 , in which
R 1 is methoxy;
R 2 is methoxy;
R 3 is methyl or ethyl;
X 1 is N; and
X 2 is CH.

12. The method of claim 1 , in which
R 1 is methoxy;
R 2 is H;
R 3 is methyl or ethyl;
X 1 is N; and
X 2 is CH.

13. The method of claim 1 , in which
R 1 is H;
R 2 is methoxy;
R 3 is methyl or ethyl;
X 1 is N; and
X 2 is CH.

14. The method of claim 1 , in which
R 1 is H;
R 2 is H;
R 3 is methyl or ethyl;
X 1 is N; and
X 2 is CH.

15. The method of claim 1 , wherein the compound of formula (I) is the (−) enantiomer in an enantiomeric purity of at least 50% ee.

16. The method of claim 15 , wherein the (−) enantiomer has an enantiomeric purity of at least 90% ee.

17. The method of claim 1 , wherein the compound of formula (I) is the racemate.

18. The method of claim 1 , for treating anxiety disorders.

19. The method of claim 1 , for treating stress-dependent anxiety-disorders.

20. The method of claim 1 , for treating depressive disorders.

21. The method of claim 20 , wherein the depressive disorders are childhood onset mood disorders.

Assignees

• Abbvie Deutschland
• Hager-Wernet Andrea

Inventors

• Netz Astrid
• Oost Thorsten
• Geneste Hervé
• Braje Wilfried
• Wernet Wolfgang
• Unger Liliane
• Hornberger Wilfried
• Lubisch Wilfried

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P25/22

  Anxiolytics · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title